Evidence map›Paper›PMID 39192652›Full record

ArticleCurrent medicinal chemistry2025

L-ascorbate Alleviates Chronic Obstructive Pulmonary Disease through the EGF/PI3K/AKT Signaling Axis.

Ji Yao, Li Zhang, Zezhi Zhou, Jiqiang Liu, Jie Cheng, Fan Long, Ting Yuan

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Garcinone C inhibits pseudorabies virus replication through EGF/PI3K/Akt axis.Frontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ji YaoDepartment of Radiology, Hengyang Medical School, The Affiliated Changsha Central Hospital, University of South China, Hengyang, China.
Li ZhangDepartment of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
Zezhi ZhouDepartment of Respiratory and Critical Care Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Jiqiang LiuDepartment of Emergency Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Jie ChengDepartment of Clinical Laboratory, Hengyang Medical School, The Affiliated Changsha Central Hospital, University of South China, Hengyang, China.
Fan LongDepartment of Health Management Center, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Ting YuanDepartment of Nutriology, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.

Funding

Hunan Provincial Natural Science Foundation of China 2021JJ30974
6 · The paper itself

Abstract

backgroundThe molecular mechanism of L-ascorbate (Vitamin C) in the treatment of Chronic Obstructive Pulmonary Disease (COPD) has not been fully explained. In this study, we aimed to explore the potential signaling pathways of L-ascorbate in the treatment of COPD.

methodsThe non-targeted metabolomics method was used to analyze the differential metabolites in the blood of healthy subjects and COPD patients. The COPD rat model was established by exposing them to Cigarette Smoke (CS). Network pharmacology, molecular docking, and molecular dynamics simulation analyses were performed to analyze the regulatory pathways of the differential metabolites.

resultsA non-targeted metabolomics analysis revealed metabolic disorders and significantly reduced levels of L-ascorbate in COPD patients compared with healthy subjects. The L-ascorbate intervention reduced lung inflammation and histological damage in COPD rat models. Network pharmacology analysis revealed 280 common targets between L-ascorbate (drug) and COPD (disease), of which seven core targets were MMP3, MME, PCNA, GCLC, SOD2, EDN1, and EGF. According to molecular docking prediction, L-ascorbate had the highest affinity with EGF. Molecular dynamics simulation indicated relatively stable EGF and L-ascorbate complexes. The PI3K/AKT signaling pathway was significantly enriched in the Kyoto Encyclopedia of Genes and Genomes (KEGG) functional analysis.

conclusionIn summary, based on network pharmacology and molecular docking analyses, this study revealed that L-ascorbate affects COPD development by regulating the PI3K/AKT signaling pathway through EGF and thus contributes to the understanding and clinical application of L-ascorbate in the treatment of COPD.

Indexed as

Ascorbic AcidEpidermal Growth FactorPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPulmonary Disease, Chronic ObstructiveSignal TransductionAnimalsFemaleHumansMaleMiddle AgedMolecular Docking SimulationMolecular Dynamics SimulationRatsRats, Sprague-DawleyAscorbic AcidEpidermal Growth FactorPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktChronic obstructive pulmonary diseaseL-ascorbatemolecular dockingnetwork pharmacologynon-targeted metabolismpathophysiology.

Identifiers

PMID39192652

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.